MMV and partners have made great strides towards contributing to the global drive towards malaria eradication as well as the SDGs. Since its foundation in 1999, 14 new medicines have been developed and brought forward with partners. The impact of these new antimalarials has been impressive. In total, they have saved almost 3 million lives.
Medicines supported by MMV and partners:
- Coartem® Dispersible (artemether-lumefantrine), a child-friendly formulation developed with Novartis for treatment of uncomplicated malaria
- Two injectable artesunate products for the treatment of severe malaria, Artesun® from Guilin and Larinate 60 from Ipca Laboratories
- Eurartesim® (dihydroartemisinin-piperaquine), developed with Alfasigma for treatment of uncomplicated malaria
- Pyramax® tablets and granules (pyronaridine-artesunate), Shin Poong's products for treatment of uncomplicated malaria in adults and children
- Two products for seasonal malaria chemoprevention (SMC) in children, from Fosun Pharma and S Kant
- Two artesunate rectal capsule (ARC) products for pre-referral management of severe malaria in children, from Cipla and Strides Pharma
- Krintafel/Kozenis1 (tafenoquine) for adults and paediatric Kozenis, two single-dose anti-relapse treatments developed with GSK
- ASAQ Winthrop® (artesunate-amodiaquine) for the treatment of acute uncomplicated P. falciparum malaria, developed by Sanofi with DNDi, transferred from DNDi to MMV to support improved access
- ASMQ (artesunate-mefloquine) for the treatment of acute uncomplicated P. falciparum malaria, developed by Farmanguinhos, DNDi and Cipla, transferred from DNDi to MMV to support improved access
→View our products and projects page for more information on each product.